Mohammed Rassool to Cost-Benefit Analysis
This is a "connection" page, showing publications Mohammed Rassool has written about Cost-Benefit Analysis.
Connection Strength
0,253
-
24-week, all-oral regimens for pulmonary rifampicin-resistant tuberculosis in TB-PRACTECAL trial sites: an economic evaluation. Lancet Glob Health. 2025 Feb; 13(2):e355-e363.
Score: 0,213
-
Cost-effectiveness of new MDR-TB regimens: study protocol for the TB-PRACTECAL economic evaluation substudy. BMJ Open. 2020 10 10; 10(10):e036599.
Score: 0,039